Pre-made Sofituzumab benchmark antibody ( Whole mAb ADC, anti-MUC16 therapeutic antibody, Anti-CA125 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-526
Pre-Made Sofituzumab biosimilar, Whole mAb ADC, Anti-MUC16 Antibody: Anti-CA125 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sofituzumab vedotin (INN; development code DMUC5754A) is a monoclonal antibody designed for the treatment of ovarian cancer. This drug was developed by Genentech/Roche.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Sofituzumab biosimilar, Whole mAb ADC, Anti-MUC16 Antibody: Anti-CA125 therapeutic antibody|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Fallopian tube cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer|